Attovia Therapeutics prices upsized IPO, securing Nasdaq listing for its clinical-stage biotherapeutics pipeline
Executive summary: Attovia Therapeutics priced its upsized initial public offering and announced the offering price for its Nasdaq‑listed shares. The IPO supplies Attovia with new capital to fund clinical development of its biotherapeutics targeting high‑unmet‑need immune diseases.
Who is involved: Attovia Therapeutics (Nasdaq: ATTO), its underwriters, and institutional investors participating in the offering.
Likely next: Shares are expected to begin regular trading on Nasdaq under the ATTO ticker following the pricing completion.
Attovia Therapeutics announced the pricing of an upsized initial public offering, setting the offer price for its shares to be traded on Nasdaq under the ticker ATTO. The move provides the clinical-stage biopharma company with additional proceeds to advance its immune‑mediated disease programs. The transaction reflects ongoing investor appetite for biotech IPOs despite broader market volatility.
Timeline
- — Grace Therapeutics Announces $10 Million Private Placement (GlobeNewswire)
- — Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
Analysis — what this means
Sectors affected
- Biopharmaceutical IPO market
Sources
- Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering — GlobeNewswire
- Grace Therapeutics Announces $10 Million Private Placement — GlobeNewswire
Related cases
- Shein’s Hong Kong debut shows a subdued start, signaling cooling enthusiasm for Chinese e‑commerce IPOs
- Unitree's IPO stumbles as its Shanghai debut shares slide roughly 30%, raising concerns about investor appetite for Chinese humanoid robotics listings
- OpenAI and Anthropic are preparing for landmark IPOs that will test public-market appetite for frontier AI labs, with Anthropic seen as holding a structural advantage
- Unitree’s strong Shanghai IPO debut signals a rebound in China’s tech‑focused capital markets while underscoring state control over listings and limited access to New York
- Lyntris prices its IPO of 17 million shares to fund defense‑technology growth
- Latigo Biotherapeutics prices upsized $345.6M IPO, reflecting strong investor appetite for non-opioid pain therapies